Form 4: Mangoceuticals Director D'Alessio Receives 100,000 Shares for Board Service

Lorraine Pamela D'Alessio, a director at Mangoceuticals, Inc., acquired 100,000 shares of common stock as compensation for services rendered as a board member.

Summary

• On June 3, 2024, Lorraine Pamela D'Alessio, a director of Mangoceuticals, Inc. (MGRX), acquired 100,000 shares of common stock.
• The shares were issued as compensation for services rendered as a member of the Board of Directors.
• The acquisition was made under the registrant's Amended and Restated 2022 Equity Incentive Plan and is exempt pursuant to Rule 16b-3.
• Following the transaction, D'Alessio directly owns 175,000 shares of Mangoceuticals, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock issuance to a board member. It's neither overwhelmingly positive nor negative.

Positives

• The issuance of shares to a director aligns their interests with those of the shareholders.
• The equity incentive plan is being utilized to compensate board members.

Industry Context

This type of equity compensation for board members is a common practice in publicly traded companies to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Granting stock options or shares to board members is a standard practice across various industries to incentivize performance and align interests with shareholders.
• Companies like Tesla, Apple, and Microsoft also utilize equity compensation plans for their board members and executives.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Mangoceuticals, MGRX, Director, Lorraine D'Alessio, Stock Acquisition, Equity Incentive Plan, Form 4, Beneficial Ownership